Raphael Pharmaceutical Inc. (RAPH) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Raphael Pharmaceutical Inc. (RAPH) trades at $1.40 with AI Score 44/100 (Grade C). Raphael Pharmaceutical Inc. is an Israeli biopharmaceutical company focused on discovering and clinically developing novel cannabinoid-based therapeutic solutions. Market cap: $28.3M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Jun 14, 2026Analyst Coverage for RAPH: RAPH does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates RAPH against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
RAPH: the 3 scored disciplines are evenly split. Dominant signal: Ken Griffin bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Raphael Pharmaceutical Inc. (RAPH) Healthcare & Pipeline Overview
Raphael Pharmaceutical Inc. is an Israeli biopharmaceutical company focused on developing novel cannabinoid-based therapeutic solutions. Its lead investigational drug targets rheumatoid arthritis, with strategic plans to broaden its pipeline into various cancer types and other autoimmune conditions, aiming to enhance patient quality of life through innovative drug discovery and clinical development.
What Is the Investment Thesis for RAPH?
Raphael Pharmaceutical Inc. (RAPH) presents a research-stage biopharmaceutical profile centered on cannabinoid-based therapeutics. The company's lead investigational drug candidate targets rheumatoid arthritis, a market with significant patient needs. Future growth is projected through planned pipeline expansion into various cancer types and other autoimmune conditions, leveraging its specialized focus on cannabinoids. However, RAPH operates with a small market capitalization of $28.3M and a high Beta of 1.85, indicating substantial volatility and limited resources. As an OTC Other listed stock, it faces inherent risks related to liquidity and disclosure. Key value drivers include successful progression of its lead candidate through clinical trials and securing subsequent regulatory approvals. Investors should closely monitor clinical trial milestones, funding initiatives, and the company's ability to navigate the complex regulatory landscape for cannabinoid-based drugs to assess its long-term viability and potential for commercialization.
Based on FMP financials and quantitative analysis
RAPH Key Highlights
Market capitalization of $28.3M, indicating a micro-cap biopharmaceutical entity.
- Beta of 1.85, suggesting significantly higher volatility compared to the broader market.
- Primary focus on developing cannabinoid-based therapeutics, with a lead candidate for rheumatoid arthritis.
- Strategic plans to broaden its pipeline into oncology and other autoimmune conditions.
- Operates as an OTC Other listed stock, implying specific trading characteristics and disclosure requirements.
Who Are RAPH's Competitors?
RAPH is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| GENH Generation Hemp, Inc. | $0.22 | +0.00% | $25.3M | 63 |
| GBLP Global Pharmatech, Inc. | $0.08 | +0.00% | $33.3M | 62 |
| ETST Earth Science Tech, Inc. | $0.12 | +14.45% | $35.3M | 61 |
| GDNSF Goodness Growth Holdings, Inc. | $0.45 | +0.00% | $61.1M | 64 |
| MNNGF Baijin Life Science Holdings Limited | $0.08 | +0.00% | $74.6M | 63 |
| SHIEF Shield Therapeutics plc | $0.07 | +0.00% | $75.3M | 62 |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109M | 66 |
| INNPF INNOCAN PHARMA Corp | $1.60 | -8.05% | $7.20M | 61 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are RAPH's Key Strengths?
Specialized focus on cannabinoid-based therapeutics, a growing area of medical research.
- Lead investigational drug candidate targeting rheumatoid arthritis, a significant market.
- Strategic plans for pipeline expansion into oncology and other autoimmune conditions.
- Presence in the pharmaceutical development space, indicating R&D capabilities.
What Are RAPH's Weaknesses?
Small market capitalization of $28.3M, indicating limited financial resources.
- Operates as an OTC Other listed stock, which can imply lower liquidity and transparency.
- High Beta of 1.85, suggesting significant stock price volatility and investment risk.
- Heavy reliance on successful clinical trial outcomes and regulatory approvals for future viability.
What Could Drive RAPH Stock Higher?
RAPH catalyst: Announcement of clinical trial milestones or data readouts for the lead rheumatoid arthritis drug candidate.
- Strategic expansion of the drug pipeline with new cannabinoid-based candidates targeting cancer or other autoimmune conditions.
- Successful securing of additional funding through equity financing, debt, or non-dilutive grants to support R&D.
- Formation of strategic partnerships or licensing agreements with larger pharmaceutical companies for drug development or commercialization.
- Positive developments in the regulatory landscape for cannabinoid-based therapeutics, potentially streamlining approval pathways.
What Are the Key Risks for RAPH?
Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- High operational risk due to a small market capitalization of $28.3M and potentially limited financial resources for extensive R&D.
- Significant market volatility indicated by a Beta of 1.85, exposing investors to substantial price fluctuations.
- Clinical trial failures, delays, or unexpected safety concerns for its investigational drug candidates, which could halt development.
- Regulatory hurdles and evolving legal frameworks surrounding cannabinoid-based therapies, impacting approval timelines and market access.
- Challenges in securing adequate and sustained funding, which is critical for advancing drug candidates through costly clinical development phases.
What Are the Growth Opportunities for RAPH?
- Advancement of Lead Rheumatoid Arthritis Candidate: Raphael Pharmaceutical Inc.'s primary growth opportunity lies in the successful progression of its lead investigational drug candidate for rheumatoid arthritis through clinical trials. The global rheumatoid arthritis market is projected to reach over $30 billion by the late 2020s, driven by the increasing prevalence of the disease and demand for effective treatments. Achieving positive clinical trial results and subsequent regulatory approval would validate the company's cannabinoid-based approach, potentially unlocking a significant revenue stream and attracting strategic partners. This milestone would also de-risk the company's pipeline and enhance its credibility within the biopharmaceutical industry.
- Pipeline Expansion into Oncology: A key strategic growth driver for Raphael Pharma is its plan to broaden its pipeline to include cannabinoid-based medicines for various cancer types. The global oncology drug market is one of the largest and fastest-growing therapeutic areas, estimated to exceed $300 billion by the early 2030s. Developing novel treatments in this space, particularly those leveraging unique mechanisms like cannabinoids, could address unmet needs in specific cancer indications or improve outcomes in combination therapies. Successful entry into oncology would diversify the company's revenue potential and significantly expand its total addressable market.
- Development for Other Autoimmune Conditions: Raphael Pharmaceutical Inc. intends to expand its focus to include other autoimmune conditions beyond rheumatoid arthritis. The broader autoimmune disease market, encompassing conditions like Crohn's disease, psoriasis, and multiple sclerosis, represents a multi-billion dollar opportunity with continuous demand for innovative therapies. By applying its expertise in cannabinoid research to these conditions, the company could develop new drug candidates that offer differentiated efficacy or safety profiles. This expansion would leverage its core scientific capabilities and open up additional patient populations for its therapeutic offerings.
- Leveraging Cannabinoid Research for New Indications: The company's specialized focus on cannabinoids presents a broad platform for future growth. As scientific understanding of cannabinoid receptors and their therapeutic potential evolves, Raphael Pharma is positioned to identify and develop treatments for a wider array of conditions beyond its current stated pipeline. This could include neurological disorders, pain management, or inflammatory conditions, each representing substantial market opportunities. Continuous investment in R&D to explore novel cannabinoid formulations and delivery methods could lead to new intellectual property and first-in-class therapies.
- Strategic Partnerships and Licensing Agreements: Given its early-stage development and small market capitalization, a significant growth opportunity for Raphael Pharmaceutical Inc. lies in forming strategic partnerships or licensing agreements with larger pharmaceutical companies. Such collaborations can provide crucial non-dilutive funding, access to advanced clinical development expertise, and established commercialization infrastructure. A successful partnership for its rheumatoid arthritis candidate or future pipeline assets could accelerate market entry, reduce financial risk, and provide a pathway to broader market penetration, validating its scientific approach and enhancing shareholder value.
What Threats Does RAPH Face?
- Clinical trial failures, delays, or unexpected adverse events for its investigational drug candidates.
- Intense competition from established pharmaceutical companies with existing treatments and larger R&D budgets.
- Evolving and potentially restrictive regulatory frameworks for cannabinoid-based therapies.
- Challenges in securing sufficient funding to support ongoing research, development, and operational costs.
What Are RAPH's Competitive Advantages?
- Proprietary cannabinoid-based drug candidates and formulations under development.
- Specialized scientific expertise in cannabinoid research, pharmacology, and clinical application.
- Potential for intellectual property protection (e.g., patents) covering drug compounds, methods of use, and manufacturing processes.
- Accumulated clinical trial data and regulatory dossiers, if successful, creating a barrier to entry for competitors.
- First-mover advantage in specific cannabinoid-based therapeutic niches, if achieved.
What Does RAPH Do?
Raphael Pharmaceutical Inc. operates as a biopharmaceutical firm headquartered in Tel Aviv-Jaffa, Israel, dedicated to the discovery and clinical development of novel therapeutic solutions. The company's core focus revolves around leveraging cannabinoids to create medicines designed to enhance patients' quality of life. This involves a rigorous research and development process, from initial compound identification and preclinical studies to advanced clinical trials. Currently, Raphael Pharma's most advanced investigational drug candidate is being developed for the management of rheumatoid arthritis, a chronic autoimmune inflammatory disease affecting millions globally. This particular focus positions the company within a significant market segment with unmet medical needs. Beyond its lead candidate, Raphael Pharmaceutical Inc. has articulated plans to strategically broaden its therapeutic pipeline. This expansion is slated to include the development of additional cannabinoid-based medicines targeting various cancer types, a field with substantial patient populations and ongoing demand for innovative treatments. Furthermore, the company intends to explore other autoimmune conditions, indicating a long-term vision to address a wider spectrum of chronic diseases where cannabinoid mechanisms could offer therapeutic benefits. Raphael Pharma's commitment to cannabinoid research places it at the forefront of an evolving area of pharmaceutical science, seeking to harness the therapeutic potential of these compounds for complex medical challenges.
What Products and Services Does RAPH Offer?
- Discovers and clinically develops novel therapeutic solutions leveraging cannabinoids.
- Focuses on enhancing patients' quality of life through innovative drug development.
- Advances a lead investigational drug candidate for the management of rheumatoid arthritis.
- Plans to broaden its pipeline to include cannabinoid-based medicines for various cancer types.
- Intends to develop treatments for other autoimmune conditions using cannabinoids.
- Conducts biopharmaceutical research and development from its headquarters in Tel Aviv-Jaffa, Israel.
How Does RAPH Make Money?
- Engages in the research and development of proprietary cannabinoid-based drug candidates.
- Aims to secure regulatory approvals for its investigational drugs to bring them to market.
- Potential future revenue generation from the sale of approved pharmaceutical products.
- May pursue licensing agreements or partnerships with larger pharmaceutical entities for development and commercialization.
- Relies on successful clinical trial outcomes and intellectual property protection for long-term viability.
What Industry Does RAPH Operate In?
Raphael Pharmaceutical Inc. operates within the dynamic and research-intensive biopharmaceutical sector, specifically targeting the drug manufacturers - specialty & generic industry. The company's unique positioning stems from its dedicated focus on cannabinoid-based therapeutic solutions, a niche but rapidly evolving segment within healthcare. The broader biopharmaceutical market is characterized by significant R&D investments, long development cycles, and high regulatory hurdles. For rheumatoid arthritis, the company's lead indication, the global market is substantial, driven by an aging population and increasing prevalence of autoimmune diseases. Competition in this space is intense, featuring established pharmaceutical giants with extensive portfolios of biologics and small molecule drugs. Raphael Pharma aims to carve out its position by leveraging the distinct pharmacological properties of cannabinoids, which may offer novel mechanisms of action or improved patient profiles compared to existing treatments. The planned expansion into oncology and other autoimmune conditions further places it within highly competitive but lucrative therapeutic areas, underscoring the need for differentiated and effective drug candidates.
Who Are RAPH's Key Customers?
- Patients diagnosed with rheumatoid arthritis, who are the target for its lead drug candidate.
- Future patient populations suffering from various cancer types, pending pipeline expansion.
- Individuals affected by other autoimmune conditions, as the company plans to broaden its therapeutic focus.
- Healthcare providers, including physicians and specialists, who would prescribe the company's approved treatments.
- Hospitals and clinics that administer pharmaceutical therapies for chronic and severe diseases.
Financial Health
Raphael Pharmaceutical Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
RAPH Valuation & Market Position
With a $28.3M market cap, Raphael Pharmaceutical Inc. sits in the micro-cap segment of the market. Relative to its peer group, RAPH's quantitative score of 44/100 is below the peer average of 63/100.
Key Financial Metrics
Return on equity for Raphael Pharmaceutical Inc. stands at 84.8%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -0.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -4.2%, the inverse of the P/E and a quick read on earnings relative to price.
Company Profile
Raphael Pharmaceutical Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Jaffa, IL. The company is led by CEO Shlomo Pilo. RAPH has traded publicly since 2023.
RAPH Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Specialized focus on cannabinoid-based therapeutics, a growing area of medical research.
- Lead investigational drug candidate targeting rheumatoid arthritis, a significant market.
- Strategic plans for pipeline expansion into oncology and other autoimmune conditions.
- Presence in the pharmaceutical development space, indicating R&D capabilities.
Bear Case
- Small market capitalization of $28.3M, indicating limited financial resources.
- Operates as an OTC Other listed stock, which can imply lower liquidity and transparency.
- High Beta of 1.85, suggesting significant stock price volatility and investment risk.
- Heavy reliance on successful clinical trial outcomes and regulatory approvals for future viability.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
RAPH Latest News
No recent news available for RAPH.
RAPH Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for RAPH.
Price Targets
Wall Street price target analysis for RAPH.
RAPH MoonshotScore
What does this score mean?
The MoonshotScore rates RAPH 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Shlomo Pilo
Unknown
Unknown
Track Record: Unknown
RAPH OTC Market Information
Raphael Pharmaceutical Inc. trades on the OTC Other tier, which is the lowest of the three OTC Markets tiers (OTCQX, OTCQB, OTC Other). Companies on the OTC Other tier are not required to meet any minimum financial standards or undergo a qualitative review by OTC Markets Group. This tier typically includes companies that are not current in their reporting, are in financial distress, or have limited public information available. Unlike companies listed on major exchanges like NYSE or NASDAQ, which have stringent listing requirements for market capitalization, share price, and corporate governance, OTC Other companies face minimal oversight, leading to higher inherent risks for investors.
- OTC Tier: OTC Other
- Limited public disclosure and transparency due to minimal reporting requirements.
- Significantly lower liquidity compared to exchange-listed stocks, leading to wider bid-ask spreads and difficulty in trading.
- Increased susceptibility to price manipulation and fraud due to less regulatory oversight.
- Difficulty in obtaining reliable financial information and company updates, hindering informed investment decisions.
- Higher volatility and potential for substantial capital loss due to the speculative nature of many OTC Other stocks.
- Verify the company's current financial statements and any available disclosures directly from the company or regulatory filings.
- Research the management team's background, experience, and track record in the biopharmaceutical industry.
- Assess the scientific validity and market potential of its cannabinoid-based drug candidates and clinical trial progress.
- Investigate any legal or regulatory actions against the company or its executives.
- Evaluate the company's funding status, burn rate, and ability to secure future capital for R&D.
- Understand the competitive landscape for its target therapeutic areas and the differentiation of its products.
- Scrutinize the company's intellectual property portfolio and patent protection.
- The company's stated focus on specific therapeutic areas (rheumatoid arthritis, cancer, autoimmune conditions) indicates a defined business objective.
- Headquarters in Tel Aviv-Jaffa, Israel, suggests an established operational base.
- The explicit mention of clinical development implies engagement in a structured R&D process, typical for biopharmaceutical firms.
- The company operates within the healthcare sector, which generally involves a higher degree of scientific rigor and regulatory oversight, even for early-stage companies.
What Investors Ask About Raphael Pharmaceutical Inc. (RAPH) — Healthcare
What does the AI Score mean for RAPH?
RAPH holds an AI Score of 44/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Raphael Pharmaceutical Inc. is an Israeli biopharmaceutical company focused on discovering and clinically developing novel cannabinoid-based therapeutic solutions. Its primary investigational drug …
What does Raphael Pharmaceutical Inc. do?
Raphael Pharmaceutical Inc. is a biopharmaceutical company based in Tel Aviv-Jaffa, Israel, specializing in the discovery and clinical development of novel therapeutic solutions. The company's core strategy involves leveraging cannabinoids to create medicines aimed at improving patients' quality of life. Currently, its primary focus is on advancing an investigational drug candidate for the treatment of rheumatoid arthritis.
What are the key growth opportunities for RAPH in healthcare?
Raphael Pharmaceutical Inc. has several key growth opportunities within the healthcare sector. Foremost is the successful progression and eventual commercialization of its lead investigational drug for rheumatoid arthritis, a market with significant unmet needs.
What are the main risks for RAPH?
Raphael Pharmaceutical Inc. faces several significant risks inherent to its stage of development and market listing. As an early-stage biopharmaceutical company, it carries substantial clinical trial risk; any failures, delays, or unexpected safety issues with its investigational drug candidates could severely impact its viability.
How does Raphael Pharmaceutical Inc. leverage cannabinoids in its drug development?
Raphael Pharmaceutical Inc. leverages cannabinoids as the foundational compounds for its novel therapeutic solutions. This involves extensive research into the specific pharmacological properties of various cannabinoids and their interactions with the human endocannabinoid system, which plays a crucial role in regulating numerous physiological processes, including pain, inflammation, and immune response.
What is the significance of RAPH's OTC Other listing for investors?
Raphael Pharmaceutical Inc.'s listing on the OTC Other tier signifies a crucial aspect for investors, primarily indicating a higher risk profile compared to companies on major exchanges like NYSE or NASDAQ. The OTC Other tier has minimal reporting requirements, leading to limited public disclosure and transparency regarding the company's financials and operations.
What are the key factors to evaluate for RAPH?
Raphael Pharmaceutical Inc. (RAPH) holds an AI score of 44/100 (low). (RAPH) presents a research-stage biopharmaceutical profile centered on cannabinoid-based therapeutics. Not financial advice.
How frequently does RAPH data refresh on this page?
RAPH's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven RAPH's recent stock price performance?
Raphael Pharmaceutical Inc. (RAPH) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized focus on cannabinoid-based therapeutics, a growing area of medical research. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- All information is derived solely from the provided source data. No external information or speculation was used.